BRCA2 and breast carcinoma: Currently, NICE clinical guidelines state that genetic testing should be offered to an individual with breast cancer if their combined BRCA1 or BRCA2 PV carrier probability is 10% or more, with fast-track genetic testing (within 4 weeks of diagnosis) currently not recommended outside the context of a clinical trial [14].